Sandostatin and Ipf - a phase IV clinical study of FDA data

Summary:

Ipf is reported as a side effect among people who take Sandostatin (octreotide acetate), especially for people who are female, 60+ old, have been taking the drug for 5 - 10 years also take Synthroid, and have Diabetes.

The phase IV clinical study analyzes which people have Ipf when taking Sandostatin. It is created by eHealthMe based on reports of 46,692 people who have side effects when taking Sandostatin from the FDA, and is updated regularly.

What is Sandostatin?

Sandostatin has active ingredients of octreotide acetate. It is often used in acromegaly. eHealthMe is studying from 46,793 Sandostatin users. Check the latest studies of Sandostatin.

What is Ipf?

Ipf is found to be associated with 2,101 drugs and 2,253 conditions by eHealthMe. Check the latest studies of Ipf.

On Jan, 10, 2026

46,692 people reported to have side effects when taking Sandostatin.
Among them, 40 people (0.09%) have Ipf.

Among these 40 people:

How long have people been on Sandostatin when they have Ipf? *

What is the gender of people who have Ipf when taking Sandostatin? *

female: 57.5 %
male: 42.5 %

What is the age of people who have Ipf when taking Sandostatin? *

What are other drugs people take besides Sandostatin? *

What are other side effects people have besides Ipf? *

Nausea And Vomiting: 22 people, 55.00%
Back Pain: 19 people, 47.50%
Diarrhea: 18 people, 45.00%
Blood Pressure Systolic Increased: 18 people, 45.00%
Injection Site Pain: 17 people, 42.50%
Headache (pain in head): 16 people, 40.00%
Fever: 15 people, 37.50%
High Blood Pressure: 14 people, 35.00%
Abdominal Pain: 14 people, 35.00%
Nausea (feeling of having an urge to vomit): 13 people, 32.50%

What are the existing conditions these people have? *

Diabetes: 9 people, 22.50%
High Blood Pressure: 7 people, 17.50%
Pancreatic Neuroendocrine Tumor: 5 people, 12.50%
Zollinger-Ellison Syndrome (increased production of the hormone gastrin from a small tumour of pancreas): 3 people, 7.50%
Neuroendocrine Tumor: 1 person, 2.50%
Neuroendocrine Carcinoma (cancer tumour that arise from cells of the endocrine (hormonal) and nervous systems): 1 person, 2.50%
Hepatic Neoplasm Malignant Non-Resectable (liver cancer non-resectable): 1 person, 2.50%
Drug Dependence: 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Sandostatin and have Ipf?

- Check whether Ipf is associated with a drug or a condition (FREE)
- Predict drug outcomes for up to one year with AI (FREE)
- Get an AI agent to monitor your drugs continuously (FREE)

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sandostatin:

Sandostatin (46,793 reports)

Ipf treatments and more:

Ipf (79,192 reports)

Browse all side effects of Sandostatin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ipf:

Ipf (2,097 drugs)

Browse all the conditions that are associated with Ipf:

Ipf (2,253 conditions)

Related publications that referenced our studies

Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .
Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on octreotide acetate (the active ingredients of Sandostatin) and Sandostatin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.